INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second most commonly diagnosed cancer in females. CRC is also the leading cause of cancer-related death in the Western world, and has exhibited a striking rise in incidence in Asian countries \[[@R1]--[@R3]\]. The etiology of CRC is multifactorial, though it is widely accepted that CRC can be caused by an accumulation of mutations in various genes \[[@R4]\]. The identification of CRC-related genes may help facilitate the early diagnosis, prevention and treatment of the disease \[[@R5]\].

The *TP53* tumor suppressor gene, which is located on chromosome 17p13, is one of the most frequently mutated in human carcinogenesis \[[@R6]\]. The encoded TP53 protein is a key mediator in many cellular processes, including cell cycle arrest, apoptosis, senescence, DNA repair, and changes in metabolism \[[@R7]\]. Consequently, *TP53* mutations may result in a loss of the protein\'s tumor suppressor function and thus contribute to the development of malignant tumors. The common *TP53* Arg72Pro polymorphism (rs1042522) at codon 72 of exon 4 is the most studied polymorphism in cancer \[[@R8]\]. The guanine to cytosine (G\>C) nucleotide exchange associated with this polymorphism leads to a nonsynonymous amino acid change from arginine to proline. The 72Arg variant of TP53 exhibits enhanced ability to localize to the mitochondria and induce apoptosis, whereas the 72Pro variant more efficiently induces cell cycle arrest \[[@R9]\].

Several studies have been conducted to investigate the association between the *TP53* Arg72Pro polymorphism and CRC. However, the results are inconsistent and conflicting. The present meta-analysis was performed to provide a more precise estimation of this association.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Our search strategy yielded a total of 545 records, which were screened to identify original research articles pertaining to TP53 and CRC. The literature search and detailed selection procedures are summarized in Figure [1](#F1){ref-type="fig"}. After the primary screening, the full text of 40 articles was retrieved for further assessment \[[@R10]--[@R49]\]. Ten of those articles were then excluded from further analysis: 6 were not case-control studies \[[@R40]--[@R45]\], 1 was based on duplicate data from another eligible study \[[@R46]\], and 3 reported a genotype distribution among the controls that was not in Hardy-Weinberg equilibrium (HWE) \[[@R47]--[@R49]\]. Two of the articles reported 2 studies each \[[@R19], [@R24]\]. Thus, 1 study in each of 28 articles and 2 studies in each of 2 articles, adds up to a total of 32 studies in 30 articles \[[@R10]--[@R39]\]. In these 32 studies that conformed to our inclusion criteria, there were 8586 CRC cases and 10275 controls. Fourteen studies involved Asian participants, 12 involved Caucasians, and 6 involved mixed populations. The population characteristics of the included studies are shown in Table [1](#T1){ref-type="table"}.

![Flow chart of study selection process](oncotarget-08-1156-g001){#F1}

###### Characteristics of the individual studies included in the meta-analysis

  First author      Year   Country     Ethnicity   Source of control   Type of CRC            Cases   Controls   HWE   Methods                      
  ----------------- ------ ----------- ----------- ------------------- ---------------------- ------- ---------- ----- --------- ----- ----- ------ ---------------------
  Olschwang^10^     1991   France      Caucasian   Population-based    Sporadic               32      34         5     49        52    14    0.97   PCR-RFLP
  Kawajiri^11^      1993   Japan       Asian       Population-based    Sporadic               36      32         16    144       165   38    0.36   Allele specific PCR
  Murata^12^        1996   Japan       Asian       Hospital-based      Sporadic               46      55         14    53        76    23    0.62   Allele specific PCR
  Wang^13^          1999   China       Asian       Hospital-based      Sporadic               18      33         10    43        70    27    0.86   PCR-RFLP
  Sayhan^14^        2001   Turkey      Mix         Population-based    Sporadic               26      30         11    21        43    12    0.20   PCR-RFLP
  Hamajima^15^      2002   Japan       Asian       Hospital-based      Sporadic               58      72         17    91        107   43    0.24   Allele specific PCR
  Gemignani^16^     2004   Spain       Caucasian   Hospital-based      Sporadic               201     133        18    202       95    19    0.09   Allele specific PCR
  Schneider^17^     2004   Germany     Caucasian   Population-based    Sporadic               26      26         5     38        41    6     0.25   PCR-SSCP
  Krüger^18^        2005   Germany     Caucasian   Population-based    Hereditary             180     95         18    150       78    17    0.13   PCR-RFLP
  Sotamaa^19^       2005   Finland     Caucasian   Population-based    Hereditary, Sporadic   231     129        19    172       125   26    0.62   PCR-SSCP
                           USA         Mix         Population-based    Hereditary             21      7          2     64        41    13    0.11   PCR-SSCP
  Koushik^20^       2006   USA         Mix         Population-based    Sporadic               228     186        28    498       351   55    0.51   Allele specific PCR
  Lima^21^          2006   Brazil      Mix         Hospital-based      Sporadic               56      38         6     58        36    6     0.90   Allele specific PCR
  Pérez^22^         2006   Argentina   Mix         Population-based    Sporadic               31      20         2     44        53    12    0.50   Allele specific PCR
  Perfumo^23^       2006   Italy       Caucasian   Hospital-based      Sporadic               28      30         2     90        49    7     0.92   PCR-RFLP
  Talseth^24^       2006   Australia   Caucasian   Population-based    Hereditary             39      19         3     10        11    0     0.10   Sequencing
                           Poland      Caucasian   Population-based    Hereditary             33      19         4     45        28    5     0.82   Sequencing
  Tan^25^           2007   Germany     Caucasian   Population-based    Sporadic               312     131        24    343       193   27    0.98   Allele specific PCR
  Zhu^26^           2007   China       Asian       Population-based    Sporadic               83      117        85    244       321   105   0.97   PCR-RFLP
  Grünhage^27^      2008   Germany     Caucasian   Hospital-based      Hereditary, Sporadic   105     72         14    123       78    19    0.20   PCR-RFLP
  Csejtei^28^       2008   Hungary     Caucasian   Population-based    Sporadic               66      32         4     62        29    6     0.31   Allele specific PCR
  Cao^29^           2009   Korean      Asian       Population-based    Sporadic               54      67         35    114       140   39    0.70   PCR-RFLP
  Polakova^30^      2009   Germany     Caucasian   Hospital-based      Sporadic               327     225        60    326       237   49    0.52   PCR-RFLP
  Mojtahedi^31^     2010   Iran        Asian       Population-based    Sporadic               46      63         23    58        77    28    0.78   Allele specific PCR
  Aizat^32^         2011   Malaysia    Asian       Hospital-based      Sporadic               70      88         44    75        101   25    0.31   PCR-RFLP
  Dastjerdi^33^     2011   Iran        Asian       Population-based    Sporadic               97      101        52    76        113   61    0.14   PCR-RFLP
  Engin^34^         2011   Turkey      Mix         Hospital-based      Sporadic               50      41         5     52        42    14    0.24   PCR-RFLP
  Joshi^35^         2011   Japan       Asian       Population-based    Sporadic               239     342        104   310       361   107   0.90   PCR-RFLP
  Song^36^          2011   Korea       Asian       Population-based    Sporadic               740     844        244   734       776   190   0.48   TaqMan
  Zhang^37^         2012   China       Asian       Hospital-based      Sporadic               147     199        98    196       271   102   0.62   MALDI-TOF
  Oh^38^            2014   Korea       Asian       Hospital-based      Sporadic               222     247        76    145       218   65    0.25   PCR-RFLP
  Singamsetty^39^   2014   India       Asian       Population-based    Sporadic               16      48         39    37        45    25    0.13   Sequencing

*HWE*, Hardy-Weinberg equilibrium; *PCR*, polymerase chain reaction; *RFLP*, restriction fragment length polymorphism; *MALDI-TOF*, Matrix-assisted laser desorption/ionization time-of-flight.

Meta-analysis results {#s2_2}
---------------------

We assessed the association between the *TP53* Arg72Pro polymorphism and CRC susceptibility by calculating an odds ratio (OR) and its 95% confidence interval (CI) under the following four genetic models: the allele model (C vs. G), the homozygote model (CC vs. GG), the dominant model (CC+GC vs. GG), and the recessive model (CC vs. GC+GG). A summary of our meta-analysis of the association between the *TP53* Arg72Pro polymorphism and CRC is shown in Table [2](#T2){ref-type="table"}. Overall, we observed no significant associations in any of the genetic models (C vs. G: OR =1.02, 95%CI 0.94-1.10; CC vs. GG: OR=1.06, 95%CI 0.90-1.25; CC+GC vs. GG: OR=1.01, 95%CI 0.91-1.11; CC vs. GC+GG: OR=1.09, 95%CI 0.95-1.24) (Figure [2](#F2){ref-type="fig"}). Further subgroup analyses were conducted to assess the effects of potential confounding factors. There was no evidence for an association between *TP53* Arg72Pro polymorphism and CRC risk in subgroup analyses based on the source of the controls or the type of CRC (Table [2](#T2){ref-type="table"}). However, when stratified based on tumor location, we found that the CC genotype increased the risk of rectal cancer (CC vs. GC+GG: OR=1.34, 95%CI 1.12-1.62), but did not alter the risk of colon cancer (CC vs. GC+GG: OR=1.14, 95%CI 0.94-1.39). When the data for rectal cancer were stratified based on ethnicity, no significant associations were observed between *TP53* Arg72Pro polymorphism and CRC risk. Similarly, no associations were found for colon cancer (Table [2](#T2){ref-type="table"}). Nonetheless, after stratification based on ethnicity, a significant risk was observed among subjects in Asian populations who carried the CC genotype (CC vs. GC+GG: OR=1.22, 95%CI 1.02-1.45), whereas no risk was observed in Caucasian and mixed populations (CC vs. GC+GG: OR=0.94, 95%CI 0.76-1.16 and OR=0.82, 95%CI 0.5-1.16, respectively). Subgroup analyses based on ethnicity revealed no significant association between *TP53* Arg72Pro polymorphism and CRC risk in Caucasian and Mixed populations.

###### Meta-analysis of the association between ***TP53*** Arg72Pro polymorphism and colorectal cancer risk

  *Subgroup*              *NO.*   *C vs. G*          *CC vs. GG*   *CC+GC vs. GG*                               *CC vs. GC+GG*                                                                                                                                                                                                          
  ----------------------- ------- ------------------ ------------- -------------------------------------------- ------------------ ------- -------------------------------------------- ------------------ ------- -------------------------------------------- ---------------------- ------------------------------------------------ ------------------------------------------------
  Overall                 32      1.02 (0.94-1.10)   0.000         0.678[^\*^](#tfn_001){ref-type="table-fn"}   1.06 (0.90-1.25)   0.000   0.489[^\*^](#tfn_001){ref-type="table-fn"}   1.01 (0.91-1.11)   0.000   0.912[^\*^](#tfn_001){ref-type="table-fn"}   1.09 (0.95-1.24)       0.017                                            0.223[^\*^](#tfn_001){ref-type="table-fn"}
  Ethnicity                                                                                                                                                                                                                                                                                                                             
   Caucasian              12      0.96 (0.88-1.05)   0.338         0.359                                        0.92 (0.74-1.15)   0.854   0.472                                        0.96 (0.86-1.06)   0.130   0.399                                        0.94 (0.76-1.16)       0.820                                            0.555
   Asian                  14      1.10 (0.98-1.23)   0.000         0.102[^\*^](#tfn_001){ref-type="table-fn"}   1.25 (0.99-1.58)   0.000   0.060[^\*^](#tfn_001){ref-type="table-fn"}   1.08 (0.93-1.26)   0.000   0.300[^\*^](#tfn_001){ref-type="table-fn"}   **1.22 (1.02-1.45)**   **0.005[^\*^](#tfn_001){ref-type="table-fn"}**   **0.026**[^\*^](#tfn_001){ref-type="table-fn"}
   Mixed                  6       0.94 (0.82-1.09)   0.056         0.416                                        0.79 (0.55-1.12)   0.244   0.181                                        0.96 (0.81-1.15)   0.057   0.663                                        0.82 (0.58-1.16)       0.385                                            0.261
  Source of controls                                                                                                                                                                                                                                                                                                                    
   Population-based       20      1.01 (0.90-1.14)   0.000         0.825[^\*^](#tfn_001){ref-type="table-fn"}   1.12 (0.89-1.41)   0.000   0.319[^\*^](#tfn_001){ref-type="table-fn"}   0.99 (0.85-1.14)   0.000   0.843[^\*^](#tfn_001){ref-type="table-fn"}   1.15 (0.97-1.36)       0.046                                            0.102[^\*^](#tfn_001){ref-type="table-fn"}
   Hospital-based         12      1.01 (0.94-1.09)   0.155         0.744                                        1.00 (0.85-1.19)   0.165   0.974                                        1.04 (0.98-1.10)   0.251   0.900                                        1.04 (0.89-1.21)       0.093                                            0.636
  Tumor location                                                                                                                                                                                                                                                                                                                        
   [Colon cancer]{.ul}    8       1.12 (0.96-1.32)   0.020         0.159[^\*^](#tfn_001){ref-type="table-fn"}   1.23 (0.88-1.73)   0.041   0.228[^\*^](#tfn_001){ref-type="table-fn"}   1.21 (0.94-1.56)   0.005   0.145[^\*^](#tfn_001){ref-type="table-fn"}   1.14 (0.94-1.39)       0.421                                            0.185
    (Caucasian)           2       1.09 (0.90-1.32)   0.456         0.365                                        1.19 (0.77-1.84)   0.160   0.432                                        1.11 (0.87-1.41)   0.942   0.410                                        1.14 (0.75-1.73)       0.104                                            0.551
    (Asian)               5       1.16 (0.86-1.55)   0.003         0.332[^\*^](#tfn_001){ref-type="table-fn"}   1.35 (0.79-2.30)   0.015   0.275[^\*^](#tfn_001){ref-type="table-fn"}   1.29 (0.78-2.13)   0.001   0.319[^\*^](#tfn_001){ref-type="table-fn"}   1.18 (0.93-1.50)       0.414                                            0.174
    (Mixed)               1       1.15 (0.93-1.41)   --            0.192                                        1.07 (0.61-1.88)   --      0.808                                        1.25 (0.97-1.62)   --      0.091                                        0.96 (0.56-1.66)       --                                               0.888
   [Rectum cancer]{.ul}   8       1.13 (0.92-1.38)   0.001         0.257[^\*^](#tfn_001){ref-type="table-fn"}   1.36 (0.93-1.99)   0.010   0.108[^\*^](#tfn_001){ref-type="table-fn"}   1.07 (0.83-1.36)   0.018   0.615[^\*^](#tfn_001){ref-type="table-fn"}   **1.34 (1.12-1.62)**   **0.125**                                        **0.002**
    (Caucasian)           2       0.90 (0.72-1.13)   0.549         0.359                                        1.00 (0.61-1.65)   0.581   0.998                                        0.82 (0.62-1.09)   0.549   0.161                                        1.11 (0.68-1.81)       0.687                                            0.671
    (Asian)               5       1.24 (0.93-1.67)   0.001         0.142[^\*^](#tfn_001){ref-type="table-fn"}   1.53 (0.88-2.66)   0.002   0.128[^\*^](#tfn_001){ref-type="table-fn"}   1.24 (0.85-1.79)   0.010   0.264[^\*^](#tfn_001){ref-type="table-fn"}   1.41 (0.97-2.05)       0.034                                            0.071[^\*^](#tfn_001){ref-type="table-fn"}
    (Mixed)               1       1.09 (0.78-1.53)   --            0.626                                        1.42 (0.64-3.15)   --      0.387                                        1.03 (0.68-1.58)   --      0.877                                        1.44 (0.66-3.11)       --                                               0.360
  Type of CRC                                                                                                                                                                                                                                                                                                                           
   [Sporadic]{.ul}        28      1.03 (0.95-1.12)   0.000         0.459[^\*^](#tfn_001){ref-type="table-fn"}   1.09 (0.92-1.29)   0.000   0.323[^\*^](#tfn_001){ref-type="table-fn"}   1.02 (0.92-1.14)   0.000   0.695[^\*^](#tfn_001){ref-type="table-fn"}   1.11 (0.97-1.27)       0.018                                            0.122[^\*^](#tfn_001){ref-type="table-fn"}
    (Caucasian)           9       0.97 (0.88-1.07)   0.069         0.594                                        0.97 (0.76-1.24)   0.904   0.803                                        0.96 (0.85-1.09)   0.077   0.540                                        0.99 (0.78-1.25)       0.838                                            0.928
    (Asian)               14      1.10 (0.98-1.23)   0.000         0.102[^\*^](#tfn_001){ref-type="table-fn"}   1.25 (0.99-1.58)   0.000   0.060[^\*^](#tfn_001){ref-type="table-fn"}   1.08 (0.93-1.26)   0.000   0.300[^\*^](#tfn_001){ref-type="table-fn"}   **1.22 (1.02-1.45)**   **0.005[^\*^](#tfn_001){ref-type="table-fn"}**   **0.026**[^\*^](#tfn_001){ref-type="table-fn"}
    (Mixed)               5       0.97 (0.84-1.11)   0.299         0.072                                        0.81 (0.56-1.17)   0.186   0.262                                        0.99 (0.83-1.19)   0.075   0.923                                        0.84 (0.59-1.19)       0.287                                            0.328
   [Hereditary]{.ul}      6       0.86 (0.73-1.01)   0.422         0.072                                        0.69 (0.45-1.04)   0.374   0.078                                        0.87 (0.71-1.06)   0.465   0.158                                        0.71 (0.47-1.07)       0.417                                            0.106
    (Caucasian)           5       0.88 (0.75-1.05)   0.474         0.148                                        0.71 (0.46-1.10)   0.284   0.124                                        0.89 (0.73-1.10)   0.551   0.290                                        0.73 (0.48-1.11)       0.300                                            0.141
    (Mixed)               1       0.57 (0.28-1.16)   --            0.118                                        0.47 (0.10-2.25)   --      0.344                                        0.51 (0.22-1.20)   --      0.123                                        0.58 (0.12-2.71)       --                                               0.486
  Genotype methods                                                                                                                                                                                                                                                                                                                      
   PCR-RFLP               14      1.04 (0.92-1.18)   0.000         0.519[^\*^](#tfn_001){ref-type="table-fn"}   1.07 (0.81-1.40)   0.000   0.634[^\*^](#tfn_001){ref-type="table-fn"}   1.04 (0.88-1.23)   0.001   0.628[^\*^](#tfn_001){ref-type="table-fn"}   1.10 (0.89-1.36)       0.011                                            0.381[^\*^](#tfn_001){ref-type="table-fn"}
   Allele specific PCR    10      0.98 (0.89-1.07)   0.153         0.636                                        0.93 (0.74-1.16)   0.453   0.518                                        0.98 (0.88-1.11)   0.119   0.791                                        0.94 (0.76-1.169)      0.348                                            0.543
   PCR-SSCP               3       0.77 (0.62-0.95)   0.383         0.013                                        0.61 (0.36-1.03)   0.510   0.065                                        0.74 (0.57-0.95)   0.514   0.020                                        0.68 (0.41-1.14)       0.559                                            0.142
   Sequencing             3       1.20 (0.65-2.22)   0.031         0.554[^\*^](#tfn_001){ref-type="table-fn"}   2.66 (1.39-5.08)   0.328   0.003                                        1.18 (0.44-3.12)   0.009   0.745[^\*^](#tfn_001){ref-type="table-fn"}   1.85 (1.08-3.16)       0.731                                            0.025

*OR* odds ratio; *95%CI* 95% confidence interval; *P~OR~*, pool *P* value; *P~h~*, *P* value of heterogeneity test;

Estimates for random-effects model; otherwise, fixed-effects model was used.

![Forest plots of TP53 Arg72Pro polymorphism and CRC risk\
**a.** allele model, **b.** homozygous model, **c.** dominant models, **d.** recessive models.](oncotarget-08-1156-g002){#F2}

Publication bias and sensitivity analysis {#s2_3}
-----------------------------------------

We used Begg\'s funnel plot and Egger\'s test to assess the publication bias of the published articles. The symmetrical funnel plot for the allele model shown in Figure [3](#F3){ref-type="fig"} suggests the findings of our meta-analysis were not affected by publication bias. The Egger\'s test results also did not suggest the existence of publication bias, as indicated by *P* values greater than 0.05 (*P*=0.098 for the allele model). The influence of each individual study on the pooled OR was assessed by performing the analysis while deleting one study at a time. Because the OR was not significantly influenced by omitting any single study (data not shown), we conclude our data are relatively stable and credible.

![Beggar\'s funnel plot of TP53 Arg72Pro polymorphism and CRC risk under the allele model](oncotarget-08-1156-g003){#F3}

DISCUSSION {#s3}
==========

The mechanisms that underlie the development of CRC are complex, and both environmental and genetic factors play important roles in the occurrence and progression of this disease \[[@R50]\]. TP53 is crucial for proper control of gene transcription, DNA synthesis and repair, cell cycle arrest, senescence and apoptosis. Mutations in *TP53* can disrupt these functions, leading to genetic instability and the progression to cancer.

In this meta-analysis, we found that the *TP53* Arg72Pro polymorphism was not associated with CRC in patients stratified based on type of CRC, genotype method or source of controls. When stratified based on ethnicity, there was a positive association between the *TP53* Arg72Pro polymorphism and CRC risk in Asian populations, but not Caucasian or mixed populations. These differences may reflect differences in genetic background and/or environmental factors. The Arg72 variant of the *TP53* Arg72Pro polymorphism is more efficient with respect to mitochondrial localization than the Pro72 variant and has a stronger capacity to induce apoptosis \[[@R51]\]. Researchers observed that the Arg72 form induced apoptosis with faster kinetics than did the Pro72 variant \[[@R52]\]. The greater apoptotic potential of the Arg72 protein stems from the greater interaction of this protein with MDM2, which facilitates nuclear export \[[@R53]\]. The two polymorphic variants of TP53 are functionally distinct, and these differences may influence cancer risk or treatment. Our result is does not confirm the findings of 2 earlier meta-analyses \[[@R54], [@R55]\]. These differences may be the result of the rigid inclusion criteria of our study. We excluded two studies with control genotypic distributions that deviated from the HWE \[[@R47], [@R48]\] and 2 studies with overlapping populations \[[@R18], [@R46]\]. We also identified 8 studies as eligible \[[@R32]--[@R39]\] that were not included in earlier meta-analyses. Thus, our meta-analysis likely provides a more precise estimate of the relationship between the *TP53* Arg72Pro polymorphism and CRC risk.

Several studies have indicated that there are multiple differences in the epidemiological, pathological and molecular features of CRCs \[[@R56]--[@R58]\]. Kapiteijn et al. indicated that rectal cancer may involve more nuclear β-catenin in the APC/β-catenin pathway than colon cancer and reported that the p53-pathway also appears to be more important in rectal cancer \[[@R57]\]. In another study, Slattery et al. found that rectal and distal colon tumors are more likely to have a p53 mutation than proximal colon tumors \[[@R58]\]. When we stratified based on tumor location, we observed a significant association between the *TP53* Arg72Pro CC genotype and rectal cancer, but no association was observed between this genotype and colon cancer. One possible explanation for this finding could be that different bacterial flora and a longer transit time in the rectum might change the contact between intestinal cells and potential carcinogens or promoters in the fecal stream, which may lead to more (exogenous) mutations of p53.

Factors known to affect the risk of CRC include gender, age, environmental factors and chronic inflammation. Joshi et al. found that men with the CC genotype and C allele had significantly higher risk for CRC than women with the same genotype \[[@R35]\]. Aizat et al. found that carriers of CC genotype aged 50 years and older were also at significantly greater risk for CRC \[[@R32]\]. However, no significant associations were found between these two confounding factors and CRC susceptibility in other studies \[[@R26], [@R29]\]. The difference may be explained by differences in the groups studied or populations and/or by differences in environmental exposure and lifestyle factors. Additional studies with a large patient cohort are needed to verify these initial observations.

Our meta-analysis had several limitations. First, we did not calculate an adjusted estimate for the association between the *TP53* Arg72Pro polymorphism and CRC risk because not all studies reported adjusted ORs. Second, because heterogeneity was obvious, even in some sub-analyses, other potential confounding factors appeared to be present in the included studies; we did not take these confounding factors into account. Third, due to an absence of information, we were unable to assess other factors such as gender, age, alcohol consumption and smoking status, which may have modified the association. Finally, potential gene-gene and gene-environment interactions were not analyzed due to a lack of relevant data.

In summary, our updated meta-analysis demonstrated that the *TP53* Arg72Pro polymorphism CC genotype may contribute to an increased risk of CRC, especially for rectal cancer and among Asians. Future well-designed studies with larger samples are needed to confirm our findings.

MATERIALS AND METHODS {#s4}
=====================

Identification of eligible studies {#s4_1}
----------------------------------

Potentially relevant articles published prior to December 2014 were identified in the PubMed, EMBASE, Web of Knowledge, and Chinese National Knowledge Infrastructure databases using the following key words: "TP53 or P53," "polymorphism or variant," and "colorectal cancer, colon or CRC." Additional studies on the topic of interest were identified by hand-searching the reference lists of the retrieved articles. When multiple publications reported on the same or overlapping data, the most recent study with the largest sample size was selected.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

The studies included in our meta-analysis were required to meet the following criteria: 1) the study was a case-control or cohort study; 2) the study investigated the association between the *TP53* Arg72Pro polymorphism and CRC risk; 3) the study provided sufficient information to estimate ORs and 95% CIs; and 4) the study had a control genotype distribution in HWE. Studies were excluded for the following reasons: 1) the study was not a case-control study; 2) the publication contained incomplete data; and 3) the study was a duplicate of a previous publication.

Data extraction {#s4_3}
---------------

Data were independently extracted by two reviewers (Dai and Sun) using a standardized data extraction form. Disagreements were resolved through discussion. The extracted data included the following items: first author, publication year, country of origin, ethnicity, source of control, sample sizes, genotype distribution in cases and controls, *P*-value for HWE, and genotyping methods.

Statistical analysis {#s4_4}
--------------------

Pooled ORs with corresponding 95% CIs were used to evaluate the strength of the observed associations. Four genetic contrast models, including allelic contrast (C vs. G), homozygote comparisons (CC vs. GG), dominant models (CC+GC vs. GG), and recessive models (CC vs. GC+GG), were applied. HWE was evaluated in the control group for each study using the χ^2^ test, and the significance level was set at *P*\<0.05. Between-study heterogeneity was assessed by calculating the *Q*-statistic and quantified using the *I^2^* value. A fixed effect model that used the Mantel-Haenszel approach was applied to calculate the pooled ORs if the between-study heterogeneity was not significant \[[@R59]\]. A random effect model that used DerSimonian and Laird\'s method was adopted when the between-study heterogeneity was obvious \[[@R60]\]. When the Q test *P*\>0.05 and *I^2^*\<50%, the fixed-effects model was used; otherwise, the random-effects model was used. Subgroup analyses were performed based on ethnicity, source of controls, tumor location and genotype method. Sensitivity analysis was performed to determine the influence of single datasets on the combined estimates. Begg\'s funnel plot and Egger\'s test were used to assess publication bias \[[@R61], [@R62]\]. All analyses were performed using Stata software version 12.0 (Stata Corp., College Station, TX), and all *P* values were two-sided.
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